

TEKLA LIFE SCIENCES INVESTORS  
Form N-PX  
August 20, 2018

**UNITED STATES  
SECURITIES AND EXCHANGE  
COMMISSION**

OMB APPROVAL  
OMB Number: 3235-0582  
Expires: March 31, 2021  
Estimated average burden  
hours per response.....7.2

Washington, D.C. 20549

**FORM N-PX**

**ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED  
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number **811- 06565**

**Tekla Life Sciences Investors**

(Exact name of registrant as specified in charter)

**100 Federal Street, 19th Floor, Boston, MA**  
(Address of principal executive offices)

**02110**  
(Zip code)

**Laura Woodward**

**Tekla Life Sciences Investors**

**100 Federal Street, 19th Floor, Boston MA 02110**

(Name and address of agent for service)

Registrant's telephone number, including area code: **617-772-8500**

Date of fiscal year end: **September 30**

## Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Date of reporting period: **7/1/17-6/30/18**

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss.239.24 and 274.5 of this chapter), to file reports with the Commission, no later than August 31 of each year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (OMB) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

---

**Item 1. Proxy Voting Record.**

---

*HQL Vote Summary*

## AC IMMUNE SA

<b>Security</b>	H00263105	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	ACIU	<b>Meeting Date</b>	27-Apr-2018
<b>Record Date</b>	13-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	In the event that at the Extraordinary Shareholders Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors	Management	For	N/A
2.A	Election of Douglas Williams as Member to the Board of Directors	Management	For	N/A
2.B	Election of Douglas Williams to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
3.a	Vote on Total Non-Performance-Related Compensation for the new Member of the Board of Directors from 27 April 2018 to 30 June 2018	Management	For	N/A
3.b	Vote on Equity for the new Member of the Board of Directors	Management	For	N/A
4.a	Share Capital Increase for Institutional Investors	Management	For	N/A
4.b	Share Capital Increase for Current Shareholders	Management	For	N/A

---

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

AC IMMUNE SA

<b>Security Ticker Symbol Record Date</b>	H00263105 ACIU 23-May-2018	<b>Meeting Type Meeting Date</b>	Annual 06-Jul-2018
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
A.	In the event that at the Annual General Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors	Management	For	N/A
1.	Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2017	Management	For	N/A
2.	Appropriation of Loss	Management	For	N/A
3.	Discharge of the Members of the Board of Directors and the Executive Committee	Management	For	N/A
4a.	Vote on Total Non-Performance-Related Compensation for Members of the Board of Directors from 1 July 2018 to 30 June 2019	Management	For	N/A
4b.	Vote on Equity for Members of the Board of Directors	Management	For	N/A
4c.	Vote on Total Non-Performance-Related Compensation for Members of the Executive Committee from 1 July 2018 to 30 June 2019	Management	For	N/A
4d.	Vote on Total Variable Compensation for Members of the Executive Committee for the current year 2018	Management	For	N/A
4e.	Vote on Equity for Members of the Executive Committee	Management	For	N/A
5a.	Re-election of Martin Velasco as member and Chairman of the Board of Directors	Management	For	N/A
5b.	Re-election of Peter Bollmann as the Member of the Board	Management	For	N/A
5c.	Re-election of Friedrich von Bohlen as the Member of the Board	Management	For	N/A
5d.	Re-election of Andrea Pfeifer as the Member of the Board	Management	For	N/A
5e.	Re-election of Detlev Riesner as the Member of the Board including granting an exception to the age limit	Management	For	N/A
5f.	Re-election of Tom Graney as the Member of the Board	Management	For	N/A
5g.	Re-election of Douglas Williams as the Member of the Board	Management	For	N/A
5h.	Election of Werner Lanthaler as the Member of the Board	Management	For	N/A
6a.	Re-election of Tom Graney to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
6b.	Re-election of Martin Velasco to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
6c.	Re-election of Doug Williams to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
7.	Re-election of the independent proxy Bugnion Ballansat Ehrler, represented by Gerald Virieux, avocat, Geneva	Management	For	N/A
8.	Election of the Auditors, PricewaterhouseCoopers SA, Pully	Management	For	N/A
9a.	Share Capital Increase for Institutional Investors	Management	For	N/A
9b.	Share Capital Increase for Current Shareholders	Management	For	N/A



## ACADIA PHARMACEUTICALS INC.

<b>Security</b>	004225108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ACAD	<b>Meeting Date</b>	06-Jun-2018
<b>Record Date</b>	13-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Julian Baker	For	For
	2	Stephen Biggar, M.D PhD	For	For
	3	Daniel Soland	For	For
2.	To approve an amendment to our 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,700,000 shares.	Management	For	For
3.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the annual meeting.	Management	For	For
4.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## ACCELERON PHARMA INC.

<b>Security</b>	00434H108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	XLRN	<b>Meeting Date</b>	06-Jun-2018
<b>Record Date</b>	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Habib J. Dable	Management	For	For
1b.	Election of Class II Director: Terrence C. Kearney	Management	For	For
1c.	Election of Class II Director: Karen L. Smith, M.D., Ph.D.	Management	For	For
2.	To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the proxy statement.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## ACHILLION PHARMACEUTICALS INC

<b>Security</b>	00448Q201	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ACHN	<b>Meeting Date</b>	31-May-2018
<b>Record Date</b>	16-Apr-2018		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Nominee removed	For	For
	2	Jason Fisherman, M.D.	For	For
2.	To approve, on an advisory basis, our executive compensation.	Management	For	For
3.	To approve an amendment and restatement of our 2015 Stock Incentive Plan.	Management	For	For
4.	To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the current fiscal year.	Management	For	For
5a.	To elect one Class III Director for a term to expire at our 2021 annual meeting of stockholders or until his successor is duly elected and qualified: Joseph Truitt	Management	For	For

---



## ADAMAS PHARMACEUTICALS, INC.

<b>Security</b>	00548A106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ADMS	<b>Meeting Date</b>	06-Jun-2018
<b>Record Date</b>	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	William W. Ericson	For	For
	2	Martha J. Demski	For	For
	3	Ivan Lieberburg MD PhD	For	For
2.	To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For

## ADAPT IMMUNE THERAPEUTICS PLC

<b>Security</b>	00653A107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ADAP	<b>Meeting Date</b>	20-Jun-2018
<b>Record Date</b>	03-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To re-elect as a director, Lawrence Alleva, who retires by rotation in accordance with the Articles of Association.	Management	For	For
2.	To re-elect as a director, David Mott, who retires by rotation in accordance with the Articles of Association.	Management	For	For
3.	To re-elect as a director, Elliott Sigal, who retires by rotation in accordance with the Articles of Association.	Management	For	For
4.	To re-appoint KPMG LLP as our U.K. statutory auditors under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. statutory accounts and reports are presented.	Management	For	For
5.	To authorize the Audit Committee to determine our U.K. statutory auditors' remuneration for the fiscal year ending December 31, 2018.	Management	For	For
6.	To receive the U.K. statutory annual accounts and reports for ...(Due to space limits, see proxy material for full proposal).	Management	For	For
7.	To receive and approve our U.K. statutory directors remuneration report for the year ended December 31, 2017.	Management	For	For
8.	To receive and approve our Directors' Remuneration Policy, which, if approved, will take effect upon conclusion of the Annual General Meeting.	Management	For	For

## AFFIMED N.V

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	N01045108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AFMD	<b>Meeting Date</b>	19-Jun-2018
<b>Record Date</b>	22-May-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
5	Discussion of the 2017 Statutory Annual Report and proposal to adopt the financial statements for the financial year 2017, as prepared in accordance with Dutch law	Management	For	For
7	Amendment of the Remuneration Policy for the Supervisory Board (the SB Remuneration Policy )	Management	For	For
8	Discharge of the managing directors for their management during the financial year 2017	Management	For	For
9	Discharge of the supervisory directors for their supervision during the financial year 2017	Management	For	For
10a	Appointment of: Dr. Mathieu Simon as a supervisory director	Management	For	For
10b	Reappointment of: Dr. Ulrich M. Grau as a supervisory director	Management	For	For
11	Appointment of the auditor for the financial year 2018	Management	For	For
12	Amendment of the articles of association	Management	For	For
13	Authorization to acquire shares	Management	For	For

---

## AGIOS PHARMACEUTICALS, INC.

<b>Security</b>	00847X104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AGIO	<b>Meeting Date</b>	31-May-2018
<b>Record Date</b>	10-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Kaye Foster	For	For
	2	Maykin Ho, Ph.D.	For	For
	3	John M. Maraganore, PhD	For	For
2.	To vote, on an advisory basis, to approve named executive officer compensation.	Management	For	For
3.	To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## AKEBIA THERAPEUTICS, INC.

<b>Security</b>	00972D105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AKBA	<b>Meeting Date</b>	14-Jun-2018
<b>Record Date</b>	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Michael D. Clayman	For	For
	2	Duane Nash	For	For
	3	Ronald C. Renaud, Jr.	For	For
	4	John P. Butler	For	For
	5	Muneer A. Satter	For	For
	6	Michael S. Wyzga	For	For
2.	Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## ALBIREO PHARMA INC.

<b>Security</b>	01345P106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALBO	<b>Meeting Date</b>	08-Jun-2018
<b>Record Date</b>	18-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

1	Ronald H.W. Cooper		For	For
2	Anne Klibanski, M.D.		For	For
3	Stephanie S. Okey, M.S.		For	For
2.	To approve the Albireo Pharma, Inc. 2018 Equity Incentive Plan.	Management	For	For
3.	To approve the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan.	Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as Albireo's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**ALDER BIOPHARMACEUTICALS, INC.**

<b>Security</b>	014339105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALDR	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Paul B. Cleveland		For	For
	2 Stephen M. Dow		For	For
	3 A. Bruce Montgomery		For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.	Management	For	For
3.	To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For

**ALEXION PHARMACEUTICALS, INC.**

<b>Security</b>	015351109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALXN	<b>Meeting Date</b>	08-May-2018
<b>Record Date</b>	12-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Felix J. Baker		For	For
	2 David R. Brennan		For	For
	3 Christopher J. Coughlin		For	For
	4 Deborah Dunsire		For	For
	5 Paul A. Friedman		For	For
	6 Ludwig N. Hantson		For	For
	7 John T. Mollen		For	For
	8 Francois Nader		For	For
	9 Judith A. Reinsdorf		For	For
	10 Andreas Rummelt		For	For
2.	Ratification of appointment by the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm.	Management	For	For
3.	Approval of a non-binding advisory vote of the 2017 compensation paid to Alexion's named executive officers.	Management	For	For
4.	To request the Board to require an independent Chairman.	Shareholder	For	Against

**ALKERMES PLC**

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	G01767105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALKS	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	23-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Floyd E. Bloom, M.D.	Management	For	For
1b.	Election of Director: Nancy L. Snyderman, M.D.	Management	For	For
1c.	Election of Director: Nancy Wysenski	Management	For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers.	Management	For	For
3.	To hold a non-binding, advisory vote, on the frequency of future advisory votes on the compensation paid to the Company's named executive officers.	Management	1 Year	For
4.	To ratify, on a non-binding, advisory basis, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board of Directors to set the independent auditor and accounting firm's remuneration.	Management	For	For
5.	To approve the Alkermes plc 2018 Stock Option and Incentive plan.	Management	For	For

---

## ALLIQUA BIOMEDICAL, INC.

<b>Security</b>	019621200	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	ALQA	<b>Meeting Date</b>	13-Sep-2017
<b>Record Date</b>	26-Jul-2017		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To ratify the filing and effectiveness of the certificate of amendment to our amended and restated certificate of incorporation filed with the secretary of state of the state of delaware on may 6, 2016 and the increase in the number of shares of authorized common stock effected thereby.	Management	For	For
2.	To approve the proposal to authorize the company s board of directors, in its discretion but prior to the annual meeting of the company s stockholders in 2018, to amend the company s certificate of incorporation to effect a reverse stock split of the company s common stock, at a ratio in the range of ...(due to space limits, see proxy statement for full proposal).	Management	For	For
3.	To approve an adjournment of the special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of any of the foregoing proposals.	Management	For	For

## ALLIQUA BIOMEDICAL, INC.

<b>Security</b>	019621309	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	ALQA	<b>Meeting Date</b>	27-Apr-2018
<b>Record Date</b>	23-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	A proposal to approve the Asset Purchase Agreement, the Asset Sale Transaction and the other transactions contemplated by the Asset Purchase Agreement ( the Asset Sale Proposal ).	Management	For	For
2.	A proposal to approve, on an advisory, non-binding basis, certain compensation that has, will or may be paid or become payable to the Company s named executive officers in connection with the asset sale ( the Advisory Proposal ).	Management	For	For
3.	A proposal to adjourn or postpone the Special Meeting of stockholders, if necessary or appropriate, for the purpose of soliciting additional votes for the approval of the Asset Sale Proposal ( the Adjournment Proposal ).	Management	For	For

## ALLIQUA BIOMEDICAL, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Security  
 Ticker Symbol  
 Record Date

019621309  
 ALQA  
 03-May-2018

Meeting Type  
 Meeting Date

Annual  
 26-Jun-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	David Johnson	For	For
	2	Joseph Leone	For	For
	3	Gary Restani	For	For
	4	Jeffrey Sklar	For	For
	5	Mark Wagner	For	For
2.	Ratification of the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For



## ALNYLAM PHARMACEUTICALS, INC.

<b>Security</b>	02043Q107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALNY	<b>Meeting Date</b>	10-May-2018
<b>Record Date</b>	15-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Dennis A. Ausiello, M.D.	Management	For	For
1b.	Election of Class II Director: John K. Clarke	Management	For	For
1c.	Election of Class II Director: Marsha H. Fanucci	Management	For	For
1d.	Election of Class II Director: David E.I. Pyott	Management	For	For
2.	To approve the 2018 Stock Incentive Plan.	Management	For	For
3.	To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.	Management	For	For
4.	To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2018.	Management	For	For

## AMARIN CORPORATION PLC

<b>Security</b>	023111206	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AMRN	<b>Meeting Date</b>	14-May-2018
<b>Record Date</b>	18-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To re-elect Mr. John F. Thero as a director.	Management	For	For
2.	To re-elect Mr. Patrick J. O. Sullivan as a director.	Management	For	For
3.	To hold an advisory (non-binding) vote to approve the compensation of the Company's named executive officers as described in full in the accompanying Proxy Statement.	Management	For	For
4.	To appoint Ernst & Young LLP as auditors of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix the auditors remuneration as described in the accompanying Proxy Statement.	Management	For	For

## AMGEN INC.

<b>Security</b>	031162100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AMGN	<b>Meeting Date</b>	22-May-2018
<b>Record Date</b>	23-Mar-2018		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Dr. Wanda M. Austin	Management	For	For
1b.	Election of Director: Mr. Robert A. Bradway	Management	For	For
1c.	Election of Director: Dr. Brian J. Druker	Management	For	For
1d.	Election of Director: Mr. Robert A. Eckert	Management	For	For
1e.	Election of Director: Mr. Greg C. Garland	Management	For	For
1f.	Election of Director: Mr. Fred Hassan	Management	For	For
1g.	Election of Director: Dr. Rebecca M. Henderson	Management	For	For
1h.	Election of Director: Mr. Frank C. Herringer	Management	For	For
1i.	Election of Director: Mr. Charles M. Holley, Jr.	Management	For	For
1j.	Election of Director: Dr. Tyler Jacks	Management	For	For
1k.	Election of Director: Ms. Ellen J. Kullman	Management	For	For
1l.	Election of Director: Dr. Ronald D. Sugar	Management	For	For
1m.	Election of Director: Dr. R. Sanders Williams	Management	For	For
2.	Advisory vote to approve our executive compensation.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2018.	Management	For	For
4.	Stockholder proposal for an annual report on the extent to which risks related to public concern over drug pricing strategies are integrated into our executive incentive compensation.	Shareholder	Against	For

## AMICUS THERAPEUTICS, INC.

<b>Security</b>	03152W109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	FOLD	<b>Meeting Date</b>	07-Jun-2018
<b>Record Date</b>	16-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Donald J. Hayden, Jr.		For	For
	2 Craig Wheeler		For	For
2.	Proposal to approve an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par value \$0.01 per share, that we are authorized to issue from 250,000,000 to 500,000,000	Management	For	For
3.	Approval of the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool	Management	For	For
4.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018	Management	For	For
5.	Approval, on an advisory basis, the Company's executive compensation	Management	For	For

## AMPHIVENA THERAPEUTICS, INC

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	20-Dec-2017
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of Amended and Restated Certificate of Incorporation	Management	For	For
2.	Approval of Bridge Loan and Waiver of Right of First Offer	Management	For	For
3.	Omnibus Resolutions	Management	For	For

## ARCA BIOPHARMA, INC.

<b>Security</b>	00211Y407	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ABIO	<b>Meeting Date</b>	31-May-2018
<b>Record Date</b>	02-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

1	Raymond L. Woosley		For	For
2	Daniel J. Mitchell		For	For
2.	To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

ARDELYX, INC

**Security** 039697107 **Meeting Type** Annual  
**Ticker Symbol** ARDX **Meeting Date** 13-Jun-2018  
**Record Date** 20-Apr-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR			
	1	William Bertrand, Jr.	For	For
	2	Annalisa Jenkins	For	For
	3	Jan M. Lundberg, Ph.D.	For	For
2.	To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young, LLP as the independent registered public accounting firm of the Company for the fiscal year ended December 31, 2018.	Management	For	For

## ARENA PHARMACEUTICALS, INC.

<b>Security</b>	040047607	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ARNA	<b>Meeting Date</b>	13-Jun-2018
<b>Record Date</b>	24-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Jayson Dallas, M.D.	For	For
	2	Oliver Fetzer, Ph.D.	For	For
	3	Jennifer Jarrett	For	For
	4	Amit D. Munshi	For	For
	5	Garry A. Neil, M.D.	For	For
	6	Tina S. Nova, Ph.D.	For	For
	7	Randall E. Woods	For	For
2.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.	Management	For	For
3.	To approve the amendment and restatement of the Arena Pharmaceuticals, Inc., 2017 Long-Term Incentive Plan to, among other things, increase the number of shares authorized for issuance under the 2017 Long-Term Incentive Plan.	Management	For	For
4.	To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2018.	Management	For	For

## ARGENX SE

<b>Security</b>	04016X101	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	ARGX	<b>Meeting Date</b>	07-Nov-2017
<b>Record Date</b>	10-Oct-2017		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment of the remuneration policy	Management	For	For
2.	authorization of the board of directors to issue shares in the share capital of the company up to a maximum of 20% of the outstanding capital at the date of the general meeting, for a period of 18 months from the general meeting, in addition to the authorization to issue shares pursuant to the exercise of options	Management	For	For
3.	Authorization of the board of directors to, insofar necessary, limit or exclude pre-emptive rights regarding an issuance of new shares for a period of 18 months from the general meeting	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

ARGENX SE

<b>Security Ticker Symbol Record Date</b>	04016X101 ARGX 10-Apr-2018	<b>Meeting Type Meeting Date</b>	Annual 08-May-2018
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
4b.	Adoption of the 2017 annual accounts	Management	For	For
4d.	Allocation of losses of the Company in the financial year 2017 to the retained earnings of the Company	Management	For	For
4e.	Proposal to release the members of the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
5a.	Appointment of James Michael Daly as non-executive director to the board of directors of the Company	Management	For	For
5b.	Re-appointment of Tim Van Hauwermeiren as executive director to the board of directors of the Company	Management	For	For
5c.	Re-appointment of David L. Lacey as non-executive director to the board of directors of the Company	Management	For	For
5d.	Re-appointment of Peter K.M. Verhaeghe as non-executive director to the board of directors of the Company	Management	For	For
5e.	Re-appointment of Werner Lanthaler as non-executive director to the board of directors of the Company	Management	For	For
6.	Authorization of the board of directors to grant options ...(due to space limits, see proxy material for full proposal).	Management	For	For
7.	Authorization of the board of directors to issue shares in the ...(due to space limits, see proxy material for full proposal).	Management	For	For
8.	Authorization of the board of directors to limit or exclude ...(due to space limits, see proxy material for full proposal).	Management	For	For
9.	Appointment of Deloitte Accountants B.V. for the 2018 financial year	Management	For	For

ASCENDIS PHARMA A S

<b>Security Ticker Symbol Record Date</b>	04351P101 ASND 19-Apr-2018	<b>Meeting Type Meeting Date</b>	Annual 29-May-2018
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Election of Chairman of the Meeting	Management	For	For
2.	Report on the Company's Activities during the Past Year	Management	For	For
3.	Presentation of Audited Annual Report with Auditor's Statement for Approval and Discharge of the Board of Directors and Management	Management	For	For
4.	Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report	Management	For	For
5a.	Election of Board Member: Albert Cha (Class II)	Management	For	For
5b.	Election of Board Member: Birgitte Volck (Class II)	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

5c.	Election of Board Member: Martin Olin (Class II)	Management	For	For
6.	Election of State-authorized Public Auditor	Management	For	For
7.	Any proposals from the Board of Directors and/or Shareholders: The Board of Directors proposes to renew the authorisation to the Board of Directors to issue warrants. Please refer to the Notice for additional information.	Management	For	For

---

## AURIS MEDICAL HOLDING AG

<b>Security</b>	H03579101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EARS	<b>Meeting Date</b>	12-Mar-2018
<b>Record Date</b>	09-Feb-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the merger between Auris Medical Holding AG (as transferring entity) and Auris Medical NewCo Holding AG (as surviving entity) according to the terms and conditions set forth by the merger agreement dated 9 February 2018 and based on the interim balance sheet of Auris Medical Holding AG as of 30 September 2017. German Version: Genehmigung der Fusion zwischen der Auris Medical Holding AG (als ubertragende Gesellschaft) und der Auris ... (due to space limits, see proxy statement for full proposal).	Management	For	For
2.	Discharge of liability for the members of the Board of Directors and the Persons entrusted with the Company's Management. German Version: Entlastung der Mitglieder des Verwaltungsrats und der mit der Geschäftsführung der Gesellschaft betrauten Personen.	Management	For	For
3.1	Approval of the Compensation of the Board of Directors. German Version: Genehmigung der Vergütung des Verwaltungsrats.	Management	For	For
3.2	Approval of the Compensation of the members of the Executive Management Committee for the 2019 financial year. German Version: Genehmigung der Vergütung der Geschäftsleitung für das Geschäftsjahr 2019.	Management	For	For
4.1	Re-election of Thomas Meyer as member and as Chairman of the Board of Directors. German Version: Wiederwahl von Thomas Meyer als Mitglied und als Präsident des Verwaltungsrats.	Management	For	For
4.2	Re-election of Armando Anido as member of the Board of Directors. German Version: Wiederwahl von Armando Anido als Mitglied des Verwaltungsrats.	Management	For	For
4.3	Re-election of Mats Peter Blom as member of the Board of Directors. German Version: Wiederwahl von Mats Peter Blom als Mitglied des Verwaltungsrats.	Management	For	For
4.4	Re-election of Calvin W. Roberts as member of the Board of Directors. German Version: Wiederwahl von Calvin W. Roberts als Mitglied des Verwaltungsrats.	Management	For	For
4.5	Election of Alain Munoz as member of the Board of Directors. German Version: Wahl von Alain Munoz als Mitglied des Verwaltungsrats.	Management	For	For
5.1	Re-election of Armando Anido as member of the Compensation Committee. German Version: Wiederwahl von Armando Anido als Mitglied des Vergütungsausschusses.	Management	For	For
5.2	Election of Alain Munoz as member of the Compensation Committee. German Version: Wahl von Alain Munoz als Mitglied des Vergütungsausschusses.	Management	For	For
6.	Re-election of Deloitte AG as Auditors. German Version: Wiederwahl von Deloitte AG als Revisionsstelle.	Management	For	For



Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

7.	Re-election of the Independent Proxy. German Version: Wiederwahl des unabhängigen Stimmrechtsvertreters.	Management	For	For
8.	General instruction on new proposals of the Board of Directors. German Version: Allgemeine Weisungen zu nicht angekündigten Anträgen / Verhandlungsgegenständen.	Management	For	For

---

## AVADEL PHARMACEUTICALS PLC

<b>Security</b>	05337M104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AVDL	<b>Meeting Date</b>	18-Jul-2018
<b>Record Date</b>	15-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Craig R. Stapleton	Management	For	For
1b.	Election of Director: Michael S. Anderson	Management	For	For
1c.	Election of Director: Peter Thornton	Management	For	For
1d.	Election of Director: Geoffrey M. Glass	Management	For	For
1e.	Election of Director: Linda S. Palczuk	Management	For	For
2.	To ratify, in a non-binding vote, the appointment of Deloitte & Touche LLP as the Company's independent registered public auditor and accounting firm for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the Audit Committee of the Board to set the independent registered public auditor and accounting firm remuneration.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company.	Management	For	For
4.	To authorize the price range at which the Company can re-allot ordinary shares that it holds as treasury shares under Irish law.	Management	For	For

## BEIGENE LTD

<b>Security</b>	07725L102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BGNE	<b>Meeting Date</b>	06-Jun-2018
<b>Record Date</b>	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	THAT Donald W. Glazer be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general ... (due to space limits, see proxy material for full proposal).	Management	For	For
2.	THAT Michael Goller be and is hereby re-elected to serve as a ... (due to space limits, see proxy material for full proposal).	Management	For	For
3.	THAT Thomas Malley be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
4.	THAT the BeiGene, Ltd. 2018 Employee Share Purchase Plan be and is hereby approved and adopted.	Management	For	For
5.		Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

	THAT the appointment of Ernst & Young Hua Ming LLP as the Company's independent registered public accounting firm for the ... (due to space limits, see proxy material for full proposal).			
6.	THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement for the Meeting, be and is hereby approved.	Management	For	For
7.	THAT, on a non-binding, advisory basis, future advisory votes on the compensation of the Company's named executive officers will be held at the frequency hereby approved.	Management	1 Year	For

---

**BELLICUM PHARMACEUTICALS INC**

<b>Security</b>	079481107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BLCM	<b>Meeting Date</b>	14-Jun-2018
<b>Record Date</b>	17-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1 Frank B. McGuyer		For	For
	2 Jon P. Stonehouse		For	For
	3 Stephen R. Davis		For	For
2.	Ratification of selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For

**BIOCLIN THERAPEUTICS, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	27-Sep-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Election of Director	Management	For	For
2.	General Authorizing Resolution	Management	For	For

**BIOCLIN THERAPEUTICS, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	24-Apr-2018
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Amendment and Restatement of Restated Certificate of Incorporation	Management	For	For
2.	Series B Preferred Stock Financing	Management	For	For
3.	Waiver of Preemptive Rights	Management	For	For
4.	Notice of Interested Party Transactions	Management	For	For
5.	Amendment of 2013 Stock and Option Grant Plan	Management	For	For
6.	General Authorizing Resolution	Management	For	For

**BIOCLIN THERAPEUTICS, INC.**

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	21-May-2018
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Election of Director	Management	For	For
2.	General Authorizing Resolution	Management	For	For

---

**BIOGEN INC.**

<b>Security</b>	09062X103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BIIB	<b>Meeting Date</b>	12-Jun-2018
<b>Record Date</b>	17-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Alexander J. Denner	Management	For	For
1b.	Election of Director: Caroline D. Dorsa	Management	For	For
1c.	Election of Director: Nancy L. Leaming	Management	For	For
1d.	Election of Director: Richard C. Mulligan	Management	For	For
1e.	Election of Director: Robert W. Pangia	Management	For	For
1f.	Election of Director: Stelios Papadopoulos	Management	For	For
1g.	Election of Director: Brian S. Posner	Management	For	For
1h.	Election of Director: Eric K. Rowinsky	Management	For	For
1i.	Election of Director: Lynn Schenk	Management	For	For
1j.	Election of Director: Stephen A. Sherwin	Management	For	For
1k.	Election of Director: Michel Vounatsos	Management	For	For
2.	To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc. s independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Say on Pay - To approve an advisory vote on executive compensation.	Management	For	For
4.	Stockholder proposal requesting certain proxy access bylaw amendments.	Shareholder	Against	For
5.	Stockholder proposal requesting a report on the extent to which risks related to public concern over drug pricing strategies are integrated into incentive compensation arrangements.	Shareholder	Against	For

**BIOHAVEN PHARMACEUTICAL HLDG CO LTD**

<b>Security</b>	G11196105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BHVN	<b>Meeting Date</b>	01-May-2018
<b>Record Date</b>	26-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1A.	Election of Director: Dr. Eric I. Aguiar	Management	For	For
1B.	Election of Director: Dr. Albert Cha	Management	For	For
1C.	Election of Director: Ms. Julia P. Gregory	Management	For	For
2.	Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal year 2018.	Management	For	For

**BIOMARIN PHARMACEUTICAL INC.**

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	09061G101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BMRN	<b>Meeting Date</b>	05-Jun-2018
<b>Record Date</b>	09-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1	Jean-Jacques Bienaime	For	For
	2	Willard Dere	For	For
	3	Michael Grey	For	For
	4	Elaine J. Heron	For	For
	5	Robert J. Hombach	For	For
	6	V. Bryan Lawlis	For	For
	7	Alan J. Lewis	For	For
	8	Richard A. Meier	For	For
	9	David E.I. Pyott	For	For
	10	Dennis J. Slamon	For	For
2.	To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2018.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.	Management	For	For

**BLUEBIRD BIO, INC.**

<b>Security</b>	09609G100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BLUE	<b>Meeting Date</b>	20-Jun-2018
<b>Record Date</b>	23-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Class II Director: John O. Agwunobi, M.D.	Management	For	For
1b.	Election of Class II Director: Mary Lynne Hedley, Ph.D	Management	For	For
1c.	Election of Class II Director: Daniel S. Lynch	Management	For	For
2.	To hold a non-binding advisory vote on the compensation paid to the Company's named executive officers.	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**BLUEPRINT MEDICINES CORPORATION**

<b>Security</b>	09627Y109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BPMC	<b>Meeting Date</b>	20-Jun-2018
<b>Record Date</b>	23-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	<b>DIRECTOR</b>	Management		
	1 Daniel S. Lynch		For	For
	2 George D. Demetri, M.D.		For	For
	3 Lynn Seely, M.D.		For	For
2.	To approve an advisory vote on named executive officer compensation.	Management	For	For
3.	To hold an advisory vote on the frequency of future advisory votes on named executive officer compensation.	Management	1 Year	For
4.	Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ended December 31, 2018.	Management	For	For



## CELGENE CORPORATION

<b>Security</b>	151020104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CELG	<b>Meeting Date</b>	13-Jun-2018
<b>Record Date</b>	19-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Mark J. Alles		For	For
	2 R W Barker, D.Phil, OBE		For	For
	3 Hans E. Bishop		For	For
	4 Michael W. Bonney		For	For
	5 Michael D. Casey		For	For
	6 Carrie S. Cox		For	For
	7 Michael A. Friedman, MD		For	For
	8 Julia A. Haller, M.D.		For	For
	9 P. A. Hemingway Hall		For	For
	10 James J. Loughlin		For	For
	11 Ernest Mario, Ph.D.		For	For
	12 John H. Weiland		For	For
2.	Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Approval, by non-binding vote, of executive compensation of the Company's named executive officers.	Management	For	For
4.	Advisory vote on stockholder proposal to request the Company's Board of Directors to amend the Company's proxy access by-law provision to eliminate the limit on the number of stockholders that can aggregate their shares to achieve the holding requirement for nomination of directors, described in more detail in the proxy statement.	Shareholder	Against	For
5.	Advisory vote on stockholder proposal to request the Company's Board of Directors to adopt a policy and amend the Company's governing documents to require that the Chairman of the Board be an independent member, described in more detail in the proxy statement.	Shareholder	For	Against

## CELLECTIS S.A.

<b>Security Ticker Symbol Record Date</b>	15117K103 CLLS 11-Jun-2018	<b>Meeting Type Meeting Date</b>	Annual 26-Jun-2018
---	----------------------------------	----------------------------------	-----------------------

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Approval of the financial statements for the financial year ended December 31, 2017	Management	For	For
2.	Approval of the consolidated financial statements for the financial year ended December 31, 2017	Management	For	For
3.	Allocation of income for the financial year ended December 31, 2017	Management	For	For
4.	Approval of the agreements referred to in articles L. 225-38 and the following sections of the French commercial code	Management	For	For
5.	Setting the amount of the attendance fees to be granted to the non-executive directors	Management	For	For
6.	Renewal of the term of office of director of Mr. Andre Choulika	Management	For	For
7.	Renewal of the term of office of director of Mr. David Sourdive	Management	For	For
8.	Renewal of the term of office of director of Mr. Alain-Paul Godard, independent director according to the rules of the U.S. Securities Exchange Act of 1934 (the Exchange Act ) and Nasdaq Stock Market	Management	For	For
9.	Renewal of the term of office of J.M.H. Conseil, as Company's Statutory Auditors	Management	For	For
10.	Renewal of the term of office of Ernst & Young et Autres, as Company's Statutory Auditors	Management	For	For
11.	Approval of 2017 Stock Option Plan and payment for the stock options or stock purchase plan adopted by the Board of Directors on October 11, 2017	Management	For	For
12.	Authorization to be given to the Board of Directors to buy back Company shares	Management	For	For
13.	Authorization to be given to the Board of Directors for the purpose of reducing the share capital through the cancellation of shares in the context of the authorization to buy back its own shares	Management	For	For
14.	Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital by issuing ordinary shares and/or any securities, with a waiver of the preferential subscription rights of the shareholders, in favor of a category of persons meeting specified characteristics	Management	For	For
15.	Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital through the issuance of ordinary shares or of any securities with a waiver of the preferential subscription rights of the shareholders, in favor of a category of persons ensuring the underwriting of the Company's equity securities that may arise as part of an equity line financing or bond financing	Management	For	For
16.	Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

immediately or in the future by issuing ordinary shares or any securities, while maintaining the preferential subscription rights of shareholders

17.	Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital through the issuance of ordinary shares and/or any securities, with waiver of the preferential subscription rights of the shareholders, through a public offering	Management	For	For
18.	Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital through the issuance of ordinary shares and/or of any securities, with waiver of the preferential subscription rights of the shareholders, through an offer to qualified investors or a restricted circle of investors within the meaning of paragraph II of article L. 411-2 of the French monetary and financial code	Management	For	For
19.	Delegation granted to the Board of Directors to increase the number of securities to be issued in case of share capital increase with or without preferential subscription rights	Management	For	For
20.	Overall limitations to the amount of issuances made under the 14th resolution, the 15th resolution, the 16th resolution, the 17th resolution, the 18th resolution, and the 19th resolution above	Management	For	For
21.	Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital by incorporation of premiums, reserves, profits or others	Management	For	For
22.	Authorization to be given to the Board of Directors to grant options to subscribe or purchase Company's shares	Management	For	For
23.	Authorization be given to the Board of Directors for the allocation of free shares existing and/or to be issued in the future	Management	For	For
24.	Delegation of authority to be granted to the Board of Directors to issue warrants giving the right to subscribe ordinary shares of the Company - Cancellation of the preferential right of subscription to the benefit of a category of persons meeting specific characteristics	Management	For	For
25.	Delegation of authority to be granted to the Board of Directors for the purpose of issuing warrants to subscribe to and/or acquire redeemable shares (BSAAR) or share subscription warrants - with a waiver of the preferential subscription rights in favor of the following category of beneficiaries: employees and corporate officers of the Company and its subsidiaries	Management	For	For
26.	Authorization for the Board of Directors to freely allocate preferred shares of the Company to the employees and and/or the executive officers of the Company and its subsidiaries entailing the waiver by the shareholders of their preferential subscription rights	Management	For	For
27.	Overall limitations to the amount of issues made under the 22nd resolution, the 23rd resolution, the 24th resolution, the 25th resolution and the 26th resolution above	Management	For	For
28.	Removal of the obligation to submit certain decisions to the Board of Directors approval, as listed in Article 14.1.1. Section 4 of the bylaws	Management	For	For
29.	Delegation to be granted to the Board of Directors for the purpose of an increase in the share capital whose subscription would be reserved to members of a company savings plan established pursuant to articles L. 3332-1 and following of the French labor code	Management	For	N/A

## CIDARA THERAPEUTICS, INC.

<b>Security</b>	171757107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CDTX	<b>Meeting Date</b>	13-Jun-2018
<b>Record Date</b>	18-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Timothy Franson	For	For
	2	Chrysa Mineo	For	For
2.	Ratification of the appointment of the company's independent registered public accounting firm for its fiscal year ending December 31, 2018	Management	For	For

## CLOVIS ONCOLOGY, INC.

<b>Security</b>	189464100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CLVS	<b>Meeting Date</b>	07-Jun-2018
<b>Record Date</b>	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Patrick J. Mahaffy	For	For
	2	M. James Barrett, Ph.D.	For	For
	3	Thorlef Spickschen	For	For
2.	Approval and ratification of our Non-Employee Director Compensation Policy.	Management	For	For
3.	Approval of an advisory proposal on compensation of the Company's named executive officers, as disclosed in the attached proxy statement.	Management	For	For
4.	Approval of an advisory proposal on the preferred frequency of the stockholder vote on the compensation of the Company's named executive officers.	Management	1 Year	For
5.	Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2018.	Management	For	For

## CRISPR THERAPEUTICS AG

<b>Security Ticker Symbol Record Date</b>	H17182108 CRSP 02-Apr-2018	<b>Meeting Type Meeting Date</b>	Annual 30-May-2018
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
1.	The approval of the annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2017.	Management	For	For
2.	The approval of the appropriation of financial results.	Management	For	For
3.	The discharge of the members of the Board of Directors and Executive Committee.	Management	For	For
4a.	Re-election of the member to the Board of Director: Rodger Novak, M.D. (as member and Chairman)	Management	For	For
4b.	Election of the member to the Board of Director: Samarth Kulkarni, Ph.D.	Management	For	For
4c.	Re-election of the member to the Board of Director: Bradley Bolzon, Ph.D.	Management	For	For
4d.	Re-election of the member to the Board of Director: Ali Behbahani, M.D.	Management	For	For
4e.	Re-election of the member to the Board of Director: Pablo Cagnoni, M.D.	Management	For	For
4f.	Re-election of the member to the Board of Director: Kurt von Emster	Management	For	For
4g.	Re-election of the member to the Board of Director: Simeon J. George, M.D.	Management	For	For
4h.	Re-election of the member to the Board of Director: Thomas Woiwode, Ph.D.	Management	For	For
5a.	Re-election of the member of the Compensation Committee: Thomas Woiwode, Ph.D.	Management	For	For
5b.	Re-election of the member of the Compensation Committee: Pablo Cagnoni, M.D.	Management	For	For
5c.	Re-election of the member of the Compensation Committee: Simeon J. George, M.D.	Management	For	For
6a.	Binding vote on total non-performance-related compensation for members of the Board of Directors from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders.	Management	For	For
6b.	Binding vote on equity for members of the Board of Directors from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders.	Management	For	For
6c.	Binding vote on total non-performance-related compensation for members of the Executive Committee from July 1, 2018 to June 30, 2019.	Management	For	For
6d.	Binding vote on total variable compensation for members of the Executive Committee for the current year ending December 31, 2018.	Management	For	For
6e.	Binding vote on equity for members of the Executive Committee from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders.	Management	For	For
7.	The approval of an increase in the Conditional Share Capital for Employee Benefit Plans.	Management	For	For
8.		Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

	The approval of the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.			
9.	The approval of increasing the maximum number of authorized share capital and extending the date by which the Board of Directors may increase authorized share capital.	Management	For	For
10.	The re-election of the independent voting rights representative.	Management	For	For
11.	The re-election of the auditors.	Management	For	For

## CYMABAY THERAPEUTICS INC

<b>Security</b>	23257D103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CBAY	<b>Meeting Date</b>	05-Jun-2018
<b>Record Date</b>	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Sujal A. Shah	For	For
	2	Robert F. Booth, Ph.D.	For	For
	3	Carl Goldfischer, M.D.	For	For
	4	Caroline Loewy	For	For
	5	Evan A. Stein, M.D. PhD	For	For
	6	Paul F. Truex	For	For
	7	Kurt von Emster	For	For
	8	Robert J. Weiland	For	For
	9	Robert J. Wills, Ph.D.	For	For
2.	To approve the CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan, as amended and restated, to, among other things, increase the aggregate number of shares of the company's common stock authorized for issuance under the plan by 1,500,000 shares.	Management	For	For
3.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of CymaBay Therapeutics, Inc. for its fiscal year ending December 31, 2018.	Management	For	For

## CYTOKINETICS, INCORPORATED

<b>Security</b>	23282W605	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CYTK	<b>Meeting Date</b>	16-May-2018
<b>Record Date</b>	03-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Robert I. Blum	For	For
	2	Robert M. Califf M.D.	For	For
	3	Sandford D. Smith	For	For
2.	Ratification of selection of Ernst & Young LLP as the independent registered public accounting firm of Cytokinetics, Incorporated for the fiscal year ending December 31, 2018.	Management	For	For
3.	Approval, on an advisory basis, of the compensation of the named executive officers.	Management	For	For

## CYTOMX THERAPEUTICS, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	23284F105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CTMX	<b>Meeting Date</b>	13-Jun-2018
<b>Record Date</b>	23-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Charles S. Fuchs	Management	For	For
1b.	Election of Director: Hoyoung Huh	Management	For	For
2.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018.	Management	For	For

---



**DERMIRA, INC.**

<b>Security</b>	24983L104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	DERM	<b>Meeting Date</b>	12-Jun-2018
<b>Record Date</b>	16-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1 Matthew K. Fust		For	For
	2 William R. Ringo		For	For
	3 Kathleen Sebelius		For	For
2.	Vote, on a non-binding advisory basis, on the compensation paid by us to our named executive officers for the year ended December 31, 2017.	Management	For	For
3.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2018.	Management	For	For
4.	Such other business as may properly come before the meeting or any adjournment thereof.	Management	Abstain	Against

**DYNAVAX TECHNOLOGIES CORPORATION**

<b>Security</b>	268158201	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	DVAX	<b>Meeting Date</b>	31-Jul-2017
<b>Record Date</b>	30-Jun-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	To approve an amendment to the company's sixth amended and restated certificate of incorporation, as amended, to increase the authorized number of shares of common stock from 69,500,000 to 139,000,000.	Management	For	For
2.	To authorize an adjournment of the meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the proposal 1.	Management	For	For

**EDITAS MEDICINE INC**

<b>Security</b>	28106W103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EDIT	<b>Meeting Date</b>	15-Jun-2018
<b>Record Date</b>	18-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

1	Andrew Hirsch		For	For
2	Boris Nikolic, M.D.		For	For
2.	Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**EIGER BIOPHARMACEUTICALS,INC**

**Security** 28249U105 **Meeting Type** Annual  
**Ticker Symbol** EIGR **Meeting Date** 12-Jun-2018  
**Record Date** 23-Apr-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
1	Thomas J. Dietz, Ph.D		For	For
2	Eldon Mayer		For	For
2.	To ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018.	Management	For	For

## ENDO INTERNATIONAL PLC

<b>Security</b>	G30401106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ENDP	<b>Meeting Date</b>	07-Jun-2018
<b>Record Date</b>	13-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Roger H. Kimmel	Management	For	For
1b.	Election of Director: Paul V. Campanelli	Management	For	For
1c.	Election of Director: Shane M. Cooke	Management	For	For
1d.	Election of Director: Nancy J. Hutson, Ph.D.	Management	For	For
1e.	Election of Director: Michael Hyatt	Management	For	For
1f.	Election of Director: Sharad S. Mansukani, M.D.	Management	For	For
1g.	Election of Director: William P. Montague	Management	For	For
1h.	Election of Director: Todd B. Sisitsky	Management	For	For
2.	To approve the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2018 and to authorize the Board of Directors, acting through the Audit Committee, to determine the independent registered public accounting firm's remuneration.	Management	For	For
3.	To approve, by advisory vote, named executive officer compensation.	Management	For	For
4.	To approve the Endo International plc Amended and Restated 2015 Stock Incentive Plan.	Management	For	For
5.	To renew the Board's existing authority to issue shares under Irish law.	Management	For	For
6.	To renew the Board's existing authority to opt-out of statutory pre-emption rights under Irish law.	Management	For	For

## EPIZYME, INC.

<b>Security</b>	29428V104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EPZM	<b>Meeting Date</b>	18-May-2018
<b>Record Date</b>	23-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Kevin Conroy		For	For
	2 Carl Goldfischer, M.D.		For	For
	3 Beth Seidenberg, M.D.		For	For
2.	Ratification of the appointment of Ernst & Young LLP as Epizyme's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## ESPERION THERAPEUTICS INC

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	29664W105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ESPR	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	26-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Class II Director: Jeffrey Berkowitz, J.D.	Management	For	For
1b.	Election of Class II Director: Antonio M. Gotto Jr., M.D., D.Phil.	Management	For	For
1c.	Election of Class II Director: Nicole Vitullo	Management	For	For
2.	To approve the advisory resolution on the compensation of our named executive officers	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018	Management	For	For

**EUTHYMICS BIOSCIENCE, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	11-Jul-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Bridge Financing	Management	For	For

**EUTHYMICS BIOSCIENCE, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	27-Sep-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Sale and Dissolution	Management	For	For
2.	Dissolution	Management	For	For
3.	General	Management	For	For

**EXELIXIS, INC.**

<b>Security</b>	30161Q104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EXEL	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	29-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.1	Election of Class I Director: Charles Cohen, Ph.D.	Management	For	For
1.2	Election of Class I Director: George Poste, DVM, Ph.D., FRS	Management	For	For
1.3	Election of Class I Director: Jack L. Wyszomierski	Management	For	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis independent registered public accounting firm for the fiscal year ending December 28, 2018.	Management	For	For
3.	To approve, on an advisory basis, the compensation of Exelixis named executive officers, as disclosed in the accompanying Proxy Statement.	Management	For	For

**FIBROGEN, INC.**

<b>Security</b>	31572Q808	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	FGEN	<b>Meeting Date</b>	05-Jun-2018
<b>Record Date</b>	09-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Class I Director: Thomas B. Neff	Management	For	For
1b.	Election of Class I Director: Jeffrey W. Henderson	Management	For	For
1c.	Election of Class I Director: James A. Schoeneck	Management	For	For
2.	To approve, on an advisory basis, the compensation of FibroGen s named executive officers, as disclosed in the proxy statement.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

3.	To ratify the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of FibroGen for the year ending December 31, 2018.	Management	For	For
----	--	------------	-----	-----

FOAMIX PHARMACEUTICALS LTD

<b>Security Ticker Symbol Record Date</b>	M46135105 FOMX 25-Oct-2017	<b>Meeting Type Meeting Date</b>	Special 27-Nov-2017
---	----------------------------------	----------------------------------	------------------------

Item	Proposal	Proposed by	Vote	For/Against Management
1.	(i) Pay mr. domzalski annual compensation of \$440,000 for his services as the chief executive officer of the company, effective as of July 1, 2017, (ii) approve mr. domzalski's cash bonus for the six month period commencing as of July 1, 2017 up to a maximum amount of \$132,000, subject to ...(due to space limits, see proxy statement for full proposal).	Management	For	For
1A.	Do you have a personal interest in the approval of this proposal #1? mark for = yes or against = no.	Management	Against	N/A
2.	Award mr. domzalski 327,720 options and 81,930 rsus under the company's 2015 Israeli share incentive plan and its 2015 U.S. addendum.	Management	For	For
2A.	Do you have a personal interest in the approval of this proposal #2? mark for = yes or against = no.	Management	Against	N/A

## FOAMIX PHARMACEUTICALS LTD

<b>Security Ticker Symbol Record Date</b>	M46135105 FOMX 10-Apr-2018	<b>Meeting Type Meeting Date</b>	Annual 08-May-2018
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
1	Appoint Kesselman & Kesselman (a member firm of PricewaterhouseCoopers International Limited, or PwC) an independent registered public accounting firm, as the Company's independent public accountants for the fiscal year ending December 31, 2018, and authorize the Board (or the Audit Committee, if such authority is delegated to it by the Board) to fix the remuneration of such independent public accountants in accordance with the volume and nature of their services.	Management	For	For
2	Ratify the election of Mr. David Domzalski as a director of the Company.	Management	For	For
3	Approve the annual equity incentive awards to the Company's non-executive directors, as set out under Proposal 3 in the Company's proxy statement.	Management	For	For
4a	Approve the equity incentive grants to Mr. Domzalski for 2017, as set out under Proposal 4(a) in the Company's proxy statement.	Management	For	For
4a1	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 4(a)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against	Management	Against	N/A
4b	Approve the terms of Mr. Domzalski's cash bonus and equity compensation for 2018, as set out under Proposal 4(b) of the Company's proxy statement.	Management	For	For
4b1	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 4(b)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against	Management	Against	N/A
5a	Approve the 2016 equity conversion bonus for Dr. Tamarkin in respect of 2016, as set out under Proposal 5(a) of the Company's proxy statement	Management	For	For
5a1	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 5(a)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against	Management	Against	N/A
5b	Approve Dr. Tamarkin's cash bonus in respect of the first half of 2017, as set out under Proposal 5(b) of the Company's proxy statement.	Management	For	For
5b1	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 5(b)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against	Management	Against	N/A
6.	Approve the Company's Amended Compensation Policy, as set out under Proposal 6 of the Company's proxy statement.	Management	For	For
6a	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 6? If you vote FOR=YES or not at all your vote may not count for the	Management	Against	N/A

Corresponding Proposal For= Yes, No=Against

---



## GALAPAGOS N V

<b>Security</b>	36315X101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GLPG	<b>Meeting Date</b>	24-Apr-2018
<b>Record Date</b>	20-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
2.	Acknowledgement and approval of the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2017 and approval of the allocation of the annual result as proposed by the board of directors.	Management	For	N/A
5.	Acknowledgement and approval of the remuneration report.	Management	For	N/A
6.	Release from liability to be granted to the directors and the statutory auditor for the performance of their duties in the course of the financial year ended 31 December 2017.	Management	For	N/A
7.1	Re-appointment of Dr. Werner Cautreels as director of the Company.	Management	For	N/A
7.2	Re-appointment of Mr. Howard Rowe as director of the Company.	Management	For	N/A
8.	Remuneration of directors.	Management	For	N/A
9.	Offer of warrants.	Management	For	N/A

---

## GALAPAGOS N V

<b>Security Ticker Symbol Record Date</b>	B44170106 GLPG NA 10-Apr-2018	<b>Meeting Type Meeting Date</b>	Annual General Meeting 24-Apr-2018
---	-------------------------------------	----------------------------------	---------------------------------------

Item	Proposal	Proposed by	Vote	For/Against Management
CMMT	Market rules require disclosure of beneficial owner information for all voted-accounts. If an account has multiple beneficial owners, you will need to-provide the breakdown of each beneficial owner name, address and share-position to your client service representative. This information is required-in order for your vote to be lodged	Non-Voting	N/A	N/A
CMMT	Important market processing requirement: a beneficial owner signed power of- attorney (poa) may be required in order to lodge and execute your voting- instructions in this market. Absence of a poa, may cause your instructions to-be rejected. If you have any questions, please contact your client service- representative	Non-Voting	N/A	N/A
1	Acknowledgement and discussion of the annual report of the board of directors- relating to the non-consolidated and consolidated annual accounts of the- company for the financial year ended on 31 december 2017, and of the report-of the statutory auditor relating to the non-consolidated annual accounts of-the company for the financial year ended on 31 december 2017	Non-Voting	N/A	N/A
2	Acknowledgement and approval of the non-consolidated annual accounts of the company for the financial year ended on 31 december 2017 and approval of the allocation of the annual result as proposed by the board of directors	Management	For	For
3	Acknowledgement and discussion of the report of the statutory auditor-relating to the consolidated annual accounts of the company for the financial-year ended on 31 december 2017	Non-Voting	N/A	N/A
4	Acknowledgement and discussion of the consolidated annual accounts of the- company for the financial year ended on 31 december 2017	Non-Voting	N/A	N/A
5	Acknowledgement and approval of the remuneration report	Management	For	For
6	Release from liability to be granted to the directors and the statutory auditor for the performance of their duties in the course of the financial year ended 31 december 2017	Management	For	For
7.I	The shareholders meeting resolves to re- appoint dr. werner cautreels (residing in boston, ma, united states of america) as director of the company, for a period of one year ending immediately after the annual shareholders meeting to be held in 2019	Management	For	For
7.II	The shareholders meeting resolves to re- appoint mr. howard rowe (residing in london, united kingdom) as director of the company, for a period of four years ending immediately after the annual shareholders meeting to be held in 2022 and, upon the proposal of the board of directors and in accordance with the advice of the company s nomination and remuneration committee, to	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

appoint mr. rowe as an independent director as he meets  
the independence criteria set forth in article 526ter of the  
belgian companies code

8	Remuneration of directors	Management	For	For
9	Offer of warrants	Management	For	For
10	Miscellaneous	Non-Voting	N/A	N/A

---

**GENOMEDX BIOSCIENCES, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	20-Nov-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Authorized Share Structure Amendment Resolution	Management	For	For
2.	Special Rights and Restrictions Resolution	Management	For	For
3.	Class C Preferred Share Issuance Resolution	Management	For	For

**GENOMEDX BIOSCIENCES, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	8-Jan-2018
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Non-shareholders as Proxyholders Resolution	Management	For	For
2.	Special Rights and Restrictions Resolution	Management	For	For

**GENOMEDX BIOSCIENCES, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	4-Feb-2018
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Non-shareholders as Proxyholders Resolution	Management	For	For
2.	Authorized Share Structure Amendment Resolution	Management	For	For
3.	Articles Amendment Resolution	Management	For	For
4.	New Preferred Share Issuance Resolution	Management	For	For

**GENOMEDX BIOSCIENCES, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	31-Mar-2018
<b>Record Date</b>	N/A		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Non-shareholders as Proxyholders Resolution	Management	For	For
2.	Authorized Share Structure Amendment Resolution	Management	For	For
3.	Articles Amendment Resolution	Management	For	For
4.	New Preferred Share Issuance Resolution	Management	For	For

**GENOMEDX BIOSCIENCES, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	9-Jul-2018
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Non-shareholders as Proxyholders Resolution	Management	For	For
2.	Domestication Resolution	Management	For	For

---

**GILEAD SCIENCES, INC.**

<b>Security</b>	375558103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GILD	<b>Meeting Date</b>	09-May-2018
<b>Record Date</b>	16-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: John F. Cogan, Ph.D.	Management	For	For
1b.	Election of Director: Jacqueline K. Barton, Ph.D.	Management	For	For
1c.	Election of Director: Kelly A. Kramer	Management	For	For
1d.	Election of Director: Kevin E. Lofton	Management	For	For
1e.	Election of Director: John C. Martin, Ph.D.	Management	For	For
1f.	Election of Director: John F. Milligan, Ph.D.	Management	For	For
1g.	Election of Director: Richard J. Whitley, M.D.	Management	For	For
1h.	Election of Director: Gayle E. Wilson	Management	For	For
1i.	Election of Director: Per Wold-Olsen	Management	For	For
2.	To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2018.	Management	For	For
3.	To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.	Management	For	For
4.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairman of the Board of Directors be an independent director.	Shareholder	Against	For
5.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board take steps to permit stockholder action by written consent.	Shareholder	Against	For

**GLAUKOS CORPORATION**

<b>Security</b>	377322102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GKOS	<b>Meeting Date</b>	31-May-2018
<b>Record Date</b>	05-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Thomas W. Burns		For	For
	2 Gilbert H. Kliman, M.D.		For	For
	3 Marc A. Stapley		For	For
2.	Approval, on an advisory basis, of the compensation of the Company's named executive officers.	Management	For	For
3.	Approval, on an advisory basis, of the frequency of future advisory votes on executive compensation.	Management	1 Year	For
4.	Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2018.	Management	For	For



Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**GLOBAL BLOOD THERAPEUTICS, INC.**

<b>Security</b>	37890U108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GBT	<b>Meeting Date</b>	20-Jun-2018
<b>Record Date</b>	23-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Scott W. Morrison		For	For
	2 Deval L. Patrick		For	For
	3 Mark L. Perry		For	For
2.	Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.	Management	For	For
3.	Recommendation, on a non-binding, advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company's named executive officers.	Management	1 Year	For
4.	Ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For
5.	Transaction of such other business as may properly come before the meeting or any adjournment or postponement thereof.	Management	For	For

**GW PHARMACEUTICALS PLC**

<b>Security</b>	36197T103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GWPH	<b>Meeting Date</b>	14-Mar-2018
<b>Record Date</b>	05-Feb-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
O1	TO RECEIVE, CONSIDER AND ADOPT THE DIRECTORS' AND AUDITORS' REPORTS AND STATEMENT OF ACCOUNTS FOR THE YEAR ENDED 30 SEPTEMBER 2017 AND NOTE THAT THE DIRECTORS DO NOT RECOMMEND PAYMENT OF A DIVIDEND	Management	For	N/A
O2	TO APPROVE THE DIRECTORS' REMUNERATION REPORT	Management	For	N/A
O3	TO APPROVE THE DIRECTORS' REMUNERATION POLICY	Management	For	N/A
O4	TO RE-ELECT JUSTIN GOVER AS A DIRECTOR	Management	For	N/A
O5	TO ELECT CATHERINE MACKAY AS A DIRECTOR	Management	For	N/A
O6	TO ELECT ALICIA SECOR AS A DIRECTOR	Management	For	N/A
O7	TO ELECT WILLIAM WALDEGRAVE AS A DIRECTOR	Management	For	N/A
O8	TO RE-APPOINT DELOITTE LLP AS AUDITOR	Management	For	N/A
O9	To authorise the Directors to determine the Auditor's remuneration	Management	For	N/A



Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

O10	To authorise the Directors to allot shares pursuant to Section 551 of the Companies Act 2006 (the 2006 Act )	Management	For	N/A
S11	Subject to the passing of Resolution 10, to authorise the ...(due to space limits, see proxy material for full proposal).	Management	For	N/A
S12	To adopt new articles of association of the Company in ...(due to space limits, see proxy material for full proposal).	Management	For	N/A

---

**IDEXX LABORATORIES, INC.**

<b>Security</b>	45168D104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	IDXX	<b>Meeting Date</b>	09-May-2018
<b>Record Date</b>	16-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Bruce L. Claflin	Management	For	For
1b.	Election of Director: Daniel M. Junius	Management	For	For
2.	Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.	Management	For	For
3.	Approval of the Adoption of the IDEXX Laboratories, Inc. 2018 Incentive Plan. To approve the Company's 2018 Stock Incentive Plan.	Management	For	For
4.	Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation.	Management	For	For

**ILLUMINA, INC.**

<b>Security</b>	452327109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ILMN	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	29-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Jay T. Flatley	Management	For	For
1b.	Election of Director: John W. Thompson	Management	For	For
1c.	Election of Director: Gary S. Guthart, Ph.D.	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 30, 2018.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.	Management	For	For
4.	To approve, on an advisory basis, a stockholder proposal to elect each director annually.	Shareholder	Against	For

**ILLUMINOSS MEDICAL, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	14-Nov-2017
<b>Record Date</b>	N/A		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Sixth Amended and Restated Certificate of Incorporation	Management	For	For
2.	Convertible Note Financing	Management	For	For
3.	Amendment of March 2017 Notes and Warrants	Management	For	For
4.	Anti-Dilution	Management	For	For
5.	General Resolutions	Management	For	For

---

## INCYTE CORPORATION

<b>Security</b>	45337C102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	INCY	<b>Meeting Date</b>	01-May-2018
<b>Record Date</b>	05-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Julian C. Baker	Management	For	For
1.2	Election of Director: Jean-Jacques Bienaime	Management	For	For
1.3	Election of Director: Paul A. Brooke	Management	For	For
1.4	Election of Director: Paul J. Clancy	Management	For	For
1.5	Election of Director: Wendy L. Dixon	Management	For	For
1.6	Election of Director: Jacquelyn A. Fouse	Management	For	For
1.7	Election of Director: Paul A. Friedman	Management	For	For
1.8	Election of Director: Herve Hoppenot	Management	For	For
2.	To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.	Management	For	For
3.	To approve amendments to the Company's Amended and Restated 2010 Stock Incentive Plan.	Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2018.	Management	For	For

## INNOVIVA INC

<b>Security</b>	45781M101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	INVA	<b>Meeting Date</b>	24-Apr-2018
<b>Record Date</b>	19-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: George W. Bickerstaff, III	Management	For	For
1b.	Election of Director: Mark DiPaolo, Esq.	Management	For	For
1c.	Election of Director: Jules Haimovitz	Management	For	For
1d.	Election of Director: Odysseas D. Kostas, M.D.	Management	For	For
1e.	Election of Director: Sarah Schlesinger, M.D.	Management	For	For
2.	Approve the non-binding advisory resolution regarding executive compensation.	Management	For	For
3.	Ratify the selection by the Audit Committee of the Board of Directors for Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## INTELLIA THERAPEUTICS, INC.

<b>Security</b>	45826J105	<b>Meeting Type</b>	Annual
-----------------	-----------	---------------------	--------

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**Ticker Symbol** NTLA **Meeting Date** 17-May-2018  
**Record Date** 04-Apr-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Frank Verwiel	Management	For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**IONIS PHARMACEUTICALS, INC.**

**Security** 462222100 **Meeting Type** Annual  
**Ticker Symbol** IONS **Meeting Date** 23-May-2018  
**Record Date** 26-Mar-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Frederick T. Muto		For	For
	2 Breaux B. Castleman		For	For
2.	To approve, by non-binding vote, executive compensation.	Management	For	For
3.	Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2018 fiscal year.	Management	For	For

**JAZZ PHARMACEUTICALS PLC**

<b>Security</b>	G50871105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	JAZZ	<b>Meeting Date</b>	02-Aug-2018
<b>Record Date</b>	06-Jun-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Peter Gray	Management	For	For
1b.	Election of Director: Kenneth W. O Keefe	Management	For	For
1c.	Election of Director: Elmar Schnee	Management	For	For
1d.	Election of Director: Catherine A. Sohn	Management	For	For
2.	To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine the independent auditors remuneration.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc s named executive officers as disclosed in the proxy statement.	Management	For	For
4.	To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc s named executive officers.	Management	1 Year	For

**JOUNCE THERAPEUTICS, INC.**

<b>Security</b>	481116101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	JNCE	<b>Meeting Date</b>	19-Jun-2018
<b>Record Date</b>	23-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1 J. Duncan Higgons		For	For
	2 Robert Tepper, M.D.		For	For
2.	Ratification of the selection of Ernst & Young LLP as the Company s independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**LEXICON PHARMACEUTICALS, INC.**

<b>Security</b>	528872302	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	LXX	<b>Meeting Date</b>	26-Apr-2018
<b>Record Date</b>	26-Feb-2018		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR			
	1	Philippe J. Amouyal	For	For
	2	Lonnell Coats	For	For
	3	Frank P. Palantoni	For	For
2.	Advisory vote to approve the compensation paid to the Company's named executive officers.	Management	For	For
3.	Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2018.	Management	For	For

**MILESTONE PHARMACEUTICALS INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	27-Jun-2018
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Acceptance of the Audited Financial Statements of the Corporation for year ended December 31, 2017	Management	For	For
2.	Election of Directors	Management	For	For
3.	Appointment of Auditors	Management	For	For
4.	Transaction of other Business	Management	For	For

## MOLECULAR TEMPLATES, INC.

<b>Security</b>	608550109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MTEM	<b>Meeting Date</b>	31-May-2018
<b>Record Date</b>	10-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Jonathan Lanfear		For	For
	2 Scott Morenstein		For	For
2.	Approve the 2018 Equity Incentive Plan.	Management	For	For
3.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending 2018.	Management	For	For
4.	Approve by an advisory vote the compensation of our named executive officers, as disclosed in the accompanying proxy statement.	Management	For	For

## MYLAN N.V.

<b>Security</b>	N59465109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MYL	<b>Meeting Date</b>	29-Jun-2018
<b>Record Date</b>	01-Jun-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Appointment of Director: Heather Bresch	Management	For	For
1B.	Appointment of Director: Hon. Robert J. Cindrich	Management	For	For
1C.	Appointment of Director: Robert J. Coury	Management	For	For
1D.	Appointment of Director: JoEllen Lyons Dillon	Management	For	For
1E.	Appointment of Director: Neil Dimick, C.P.A.	Management	For	For
1F.	Appointment of Director: Melina Higgins	Management	For	For
1G.	Appointment of Director: Harry A. Korman	Management	For	For
1H.	Appointment of Director: Rajiv Malik	Management	For	For
1I.	Appointment of Director: Mark W. Parrish	Management	For	For
1J.	Appointment of Director: Pauline van der Meer Mohr	Management	For	For
1K.	Appointment of Director: Randall L. (Pete) Vanderveen, Ph.D.	Management	For	For
1L.	Appointment of Director: Sjoerd S. Vollebregt	Management	For	For
2.	Approval, on an advisory basis, of the compensation of the named executive officers of the Company	Management	For	For
3.	Adoption of the Dutch annual accounts for fiscal year 2017	Management	For	For
4.	Ratification of the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2018	Management	For	For
5.	Instruction to Deloitte Accountants B.V. for the audit of the Company's Dutch statutory annual accounts for fiscal year 2018	Management	For	For
6.		Management	For	For



Authorization of the Board to acquire shares in the capital  
of the Company

---

**MYOVANT SCIENCES LTD.**

<b>Security</b>	G637AM102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MYOV	<b>Meeting Date</b>	18-Aug-2017
<b>Record Date</b>	14-Jul-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.1	ELECTION OF CLASS I DIRECTOR: MARK ALTMAYER	Management	For	For
1.2	ELECTION OF CLASS I DIRECTOR: TERRIE CURRAN	Management	For	For
1.3	ELECTION OF CLASS I DIRECTOR: KEITH MANCHESTER, M.D.	Management	For	For
2.	TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF ERNST & YOUNG LLP AS MYOVANT S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR MYOVANT S FISCAL YEAR ENDING MARCH 31, 2018, TO APPOINT ERNST & YOUNG LLP AS AUDITOR FOR STATUTORY PURPOSES UNDER THE BERMUDA COMPANIES ACT 1981, AS AMENDED, FOR MYOVANT S ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).	Management	For	For

**MYOVANT SCIENCES LTD.**

<b>Security</b>	G637AM102	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	MYOV	<b>Meeting Date</b>	09-Feb-2018
<b>Record Date</b>	22-Jan-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	To approve an amendment to our Bye-laws to declassify the Board of Directors.	Management	For	For
2.	To approve an amendment to our Bye-laws to modify shareholder proposal and nomination procedures.	Management	For	For
3.	To approve an amendment to our Bye-laws to eliminate all supermajority voting requirements.	Management	For	For
4.	To approve an amendment to our Bye-laws to modify certain director removal and vacancy requirements.	Management	For	For
5.	To approve an amendment to our Bye-laws to revise certain other provisions in our Bye-laws.	Management	For	For

## NABRIVA THERAPEUTICS PLC

<b>Security</b>	G63637105	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	NBRV	<b>Meeting Date</b>	15-Sep-2017
<b>Record Date</b>	04-Aug-2017		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: DANIEL BURGESS	Management	For	For
1.2	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: AXEL BOLTE	Management	For	For
1.3	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: CARRIE BOURDOW	Management	For	For
1.4	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: COLIN BROOM	Management	For	For
1.5	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: MARK CORRIGAN	Management	For	For
1.6	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: CHARLES A. ROWLAND, JR.	Management	For	For
1.7	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: GEORGE H. TALBOT	Management	For	For
1.8	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: STEPHEN WEBSTER	Management	For	For
2.	TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	TO APPROVE THE ADOPTION OF THE COMPANY S 2017 SHARE INCENTIVE PLAN.	Management	For	For

## NANOSTRING TECHNOLOGIES, INC.

<b>Security</b>	63009R109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NSTG	<b>Meeting Date</b>	12-Jun-2018
<b>Record Date</b>	13-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Elisha W. Finney	For	For
	2	Gregory Norden	For	For
	3	Charles P. Waite	For	For
2.		Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2018.

**NATERA, INC.**

<b>Security</b>	632307104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NTRA	<b>Meeting Date</b>	16-May-2018
<b>Record Date</b>	26-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR			
	1	Roelof F. Botha	For	For
	2	Todd Cozzens	For	For
	3	Matthew Rabinowitz	For	For
2.	Proposal to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## NEKTAR THERAPEUTICS

<b>Security</b>	640268108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NKTR	<b>Meeting Date</b>	26-Jun-2018
<b>Record Date</b>	27-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Jeff Ajer	Management	For	For
1b.	Election of Director: Robert B. Chess	Management	For	For
1c.	Election of Director: Roy A. Whitfield	Management	For	For
2.	To approve an amendment and restatement of the 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the 2017 Performance Incentive Plan by 10,900,000 shares to a total reserve of 19,200,000 shares.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
4.	To approve a non-binding advisory resolution regarding our executive compensation (a say-on-pay vote).	Management	For	For

## NEUROCRINE BIOSCIENCES, INC.

<b>Security</b>	64125C109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NBIX	<b>Meeting Date</b>	24-May-2018
<b>Record Date</b>	29-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 William H Rastetter PhD		For	For
	2 George J. Morrow		For	For
2.	Advisory vote to approve the compensation paid to the Company's named executive officers.	Management	For	For
3.	To approve an amendment to the Company's 2011 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder from 17,000,000 to 19,000,000.	Management	For	For
4.	To approve the Company's 2018 Employee Stock Purchase Plan.	Management	Against	Against
5.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## NEWLINK GENETICS CORPORATION

<b>Security</b>	651511107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NLNK	<b>Meeting Date</b>	23-May-2018

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**Record Date** 26-Mar-2018

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR			
	1	Chad A. Johnson	For	For
	2	Ernest J. Talarico, III	For	For
	3	Lota S. Zoth	For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.	Management	For	For
3.	To indicate, on an advisory basis, the preferred frequency of future advisory votes on the compensation of our named executive officers.	Management	1 Year	For
4.	To ratify the selection, by the Audit Committee of the Board of Directors, of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For

## NOVAVAX, INC.

<b>Security</b>	670002104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NVAX	<b>Meeting Date</b>	14-Jun-2018
<b>Record Date</b>	18-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1	Richard H. Douglas Ph.D	For	For
	2	Gary C. Evans	For	For
2.	To consider and vote whether to approve, on an advisory basis, the compensation paid to our Named Executive Officers.	Management	For	For
3.	To amend and restate the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, to increase the number of shares of the Company's common stock, par value \$0.01, available for issuance thereunder by 20,000,000 shares.	Management	For	For
4.	To amend and restate the Novavax, Inc. Amended and Restated 2013 Employee Stock Purchase Plan, to increase the number of shares of the Company's common stock, par value \$0.01, available for issuance thereunder by 4,000,000 shares.	Management	For	For
5.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## NUCANA PLC

<b>Security Ticker Symbol Record Date</b>	67022C106 NCNA 24-May-2018	<b>Meeting Type Meeting Date</b>	Annual 27-Jun-2018
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
O1	To re-elect (as a Class III director) Isaac Cheng, who is retiring in accordance with the Articles of Association of the Company, as a director of the Company.	Management	For	N/A
O2	To re-elect (as a Class III director) Martin Mellish, who is retiring by rotation in accordance with the Articles of Association of the Company, as a director of the Company.	Management	For	N/A
O3	To re-elect (as a Class III director) Adam George, who is retiring by rotation in accordance with the Articles of Association of the Company, as a director of the Company.	Management	For	N/A
O4	To elect (as a Class II director) Cyrille Leperlier, who is standing for election for the remaining portion of his term of office, as a director of the Company.	Management	For	N/A
O5	To re-appoint Ernst & Young LLP as auditors of the Company to hold office from the conclusion of this meeting until the conclusion of the next annual general meeting of the Company.	Management	For	N/A
O6	To authorise the directors to determine the remuneration of the auditors of the Company.	Management	For	N/A
O7	To receive the Company's audited accounts for the financial year ended 31 December 2017, together with the strategic report, directors' report and auditors' report on those accounts.	Management	For	N/A
O8	To receive and approve the Directors' Remuneration Report (other than the part containing the Directors' Remuneration Policy) for the financial year ended 31 December 2017.	Management	For	N/A
O9	To receive and approve the Directors' Remuneration Policy, such policy to take effect from the date on which this resolution is passed.	Management	For	N/A
O10	That the directors be generally and unconditionally authorised pursuant to Section 551 of the Companies Act 2006 (the 'Act') to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of GBP 640,000. This authority shall, unless previously renewed, revoked or varied by the Company in general meeting, expire on the conclusion of the annual general meeting ...(due to space limits, see proxy material for full proposal).	Management	For	N/A
S11	That, subject to the passing of resolution 10, the directors be empowered pursuant to Section 570 of the Act to allot equity securities (as defined in Section 560 of the Act) for cash under the authority given by that resolution as if Section 561 (1) of the Act did not apply to any such allotment, provided that such authority shall be limited to the allotment of equity securities up to a nominal amount of GBP 640,000, such authority to expire on the conclusion of the annual general ...(due to space limits, see proxy	Management	For	N/A



material for full proposal).

**OVID THERAPEUTICS INC.**

<b>Security</b>	690469101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	OVID	<b>Meeting Date</b>	06-Jun-2018
<b>Record Date</b>	11-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1 Douglas Williams		For	For
	2 Barbara Duncan		For	For
2.	Ratification of the selection of the independent registered public accounting firm.	Management	For	For

**PIERIS PHARMACEUTICALS, INC.**

<b>Security</b>	720795103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PIRS	<b>Meeting Date</b>	24-Jul-2018
<b>Record Date</b>	25-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Christopher P. Kiritsy	For	For
	2	Jean-Pierre Bizzari	For	For
2.	Approve the Company's 2018 Employee, Director and Consultant Equity Incentive Plan.	Management	For	For
3.	Approve the Company's 2018 Employee Stock Purchase Plan.	Management	For	For
4.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**PORTOLA PHARMACEUTICALS, INC.**

<b>Security</b>	737010108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PTLA	<b>Meeting Date</b>	08-Jun-2018
<b>Record Date</b>	12-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Dennis Fenton, Ph.D.	For	For
	2	Charles Homcy, M.D.	For	For
	3	David C. Stump, M.D.	For	For
2.	To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 100,000,000 to 150,000,000 shares.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.	Management	For	For
4.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**PROTAGONIST THERAPEUTICS INC**

<b>Security</b>	74366E102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PTGX	<b>Meeting Date</b>	29-May-2018
<b>Record Date</b>	09-Apr-2018		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR			
	1	Chaitan Khosla, Ph.D.	For	For
	2	William D. Waddill	For	For
	3	Lewis T Williams MD PhD	For	For
2.	To ratify the selection by the Audit Committee of the Board of PricewaterhouseCoopers LLP as Protagonist Therapeutics independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**PTC THERAPEUTICS, INC.**

<b>Security</b>	69366J200	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PTCT	<b>Meeting Date</b>	13-Jun-2018
<b>Record Date</b>	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Michael Schmertzler	For	For
	2	G D Steele Jr., MD, PhD	For	For
2.	Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Advisory vote to approve named executive officer compensation.	Management	For	For

**PUMA BIOTECHNOLOGY, INC.**

<b>Security</b>	74587V107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PBYI	<b>Meeting Date</b>	12-Jun-2018
<b>Record Date</b>	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Alan H. Auerbach	For	For
	2	Michael P. Miller	For	For
	3	Jay M. Moyes	For	For
	4	Adrian M. Senderowicz	For	For
	5	Troy E. Wilson	For	For
	6	Frank E. Zavr1	For	For
2.	Ratification of the selection of KPMG LLP as independent registered public accounting firm of Puma Biotechnology, Inc. for the fiscal year ending December 31, 2018.	Management	For	For
3.	Advisory (non-binding) vote to approve the compensation of Puma Biotechnology, Inc.'s named executive officers.	Management	For	For
4.	Advisory (non-binding) vote to approve the frequency of future votes on Puma Biotechnology, Inc.'s executive compensation.	Management	1 Year	For

**RA PHARMACEUTICALS, INC.**

<b>Security</b>	74933V108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	RARX	<b>Meeting Date</b>	28-Jun-2018
<b>Record Date</b>	30-Apr-2018		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR			
	1	Robert Heft, Ph.D.	For	For
	2	Rajeev Shah	For	For
2.	To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**REGENERON PHARMACEUTICALS, INC.**

<b>Security Ticker Symbol</b>	75886F107 REGN	<b>Meeting Type</b>	Annual
<b>Record Date</b>	12-Apr-2018	<b>Meeting Date</b>	08-Jun-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Arthur F. Ryan	Management	For	For
1.2	Election of Director: George L. Sing	Management	For	For
1.3	Election of Director: Marc Tessier-Lavigne	Management	For	For
2.	Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

**REVANCE THERAPEUTICS, INC.**

<b>Security</b>	761330109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	RVNC	<b>Meeting Date</b>	10-May-2018
<b>Record Date</b>	13-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Angus C. Russell	Management	For	For
1b.	Election of Director: Phyllis Gardner, M.D.	Management	For	For
1c.	Election of Director: Julian S. Gangolli	Management	For	For
2.	Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year 2018.	Management	For	For

**SAGE THERAPEUTICS, INC.**

<b>Security</b>	78667J108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	SAGE	<b>Meeting Date</b>	06-Jun-2018
<b>Record Date</b>	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Geno Germano	For	For
	2	Steven Paul	For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Approve, on an advisory basis, the compensation of the named executive officers.	Management	For	For

**SAREPTA THERAPEUTICS INC.**

<b>Security</b>	803607100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	SRPT	<b>Meeting Date</b>	06-Jun-2018
<b>Record Date</b>	11-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1A	ELECTION OF GROUP I DIRECTOR: Michael W. Bonney	Management	For	For
1B	ELECTION OF GROUP I DIRECTOR: Douglas S. Ingram	Management	For	For
1C	ELECTION OF GROUP I DIRECTOR: Hans Wigzell, M.D., Ph.D.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

2.	ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION	Management	For	For
3.	APPROVAL OF THE COMPANY'S 2018 EQUITY INCENTIVE PLAN	Management	For	For
4.	RATIFICATION OF KPMG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2018	Management	For	For

---

## SEATTLE GENETICS, INC.

<b>Security</b>	812578102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	SGEN	<b>Meeting Date</b>	18-May-2018
<b>Record Date</b>	22-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1 Clay B. Siegall		For	For
	2 Felix Baker		For	For
	3 Nancy A. Simonian		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	To approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2007 Equity and Incentive Plan to, among other changes, increase the aggregate number of shares of common stock authorized for issuance thereunder by 6,000,000.	Management	For	For
4.	Advisory vote to approve the compensation of the Company's named executive officers as disclosed in the Company's proxy statement.	Management	For	For



## SHIRE PLC

<b>Security Ticker Symbol Record Date</b>	82481R106 SHPG 22-Mar-2018	<b>Meeting Type Meeting Date</b>	Annual 24-Apr-2018
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To receive the Company's Annual Report and Accounts for the year ended December 31, 2017.	Management	For	For
2.	To approve the Directors' Remuneration Report, excluding the Directors' Remuneration Policy, set out on pages 78 to 108 of the Annual Report and Accounts for the year ended December 31, 2017.	Management	For	For
3.	To approve the Directors' Remuneration Policy, contained within the Directors' Remuneration Report and set out on pages 86 to 95 of the Annual Report and Accounts for the year ended December 31, 2017, to take effect after the end of the Annual General Meeting on April 24, 2018.	Management	For	For
4.	To re-elect Olivier Bohuon as a Director.	Management	For	For
5.	To re-elect Ian Clark as a Director.	Management	For	For
6.	To elect Thomas Dittrich as a Director.	Management	For	For
7.	To re-elect Gail Fosler as a Director.	Management	For	For
8.	To re-elect Steven Gillis as a Director.	Management	For	For
9.	To re-elect David Ginsburg as a Director.	Management	For	For
10.	To re-elect Susan Kilsby as a Director.	Management	For	For
11.	To re-elect Sara Mathew as a Director.	Management	For	For
12.	To re-elect Flemming Ornskov as a Director.	Management	For	For
13.	To re-elect Albert Stroucken as a Director.	Management	For	For
14.	To re-appoint Deloitte LLP as the Company's Auditor until the conclusion of the next Annual General Meeting of the Company.	Management	For	For
15.	To authorize the Audit, Compliance & Risk Committee to determine the remuneration of the Auditor.	Management	For	For
16.	That the authority to allot Relevant Securities (as defined in the Company's Articles of Association (the "Articles")) conferred on the Directors by Article 10 paragraph (B) of the Articles be renewed and for this purpose the Authorised Allotment Amount shall be: (a) GBP 15,187,600.85 of Relevant Securities. (b) solely in connection with an allotment pursuant to an offer by way of a Rights Issue (as defined in the Articles, but only if and to the extent that such offer is ...(due to space limits, see proxy material for full proposal).	Management	For	For
17.	That, subject to the passing of Resolution 16, the authority to allot equity securities (as defined in the Company's Articles of Association (the "Articles")) wholly for cash conferred on the Directors by Article 10 paragraph (D) of the Articles be renewed and for this purpose the Non Pre-emptive Amount (as defined in the Articles) shall be GBP 2,278,140.10 and the Allotment Period shall be the period commencing on April 24, 2018, and ending on the earlier of the close of business on ...(due to space limits, see proxy material for full proposal).	Management	For	For
18.		Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

That, subject to the passing of Resolutions 16 and 17 and for the purpose of the authority to allot equity securities (as defined in the Company's Articles of Association (the Articles)) wholly for cash conferred on the Directors by Article 10 paragraph (D) of the Articles and renewed by Resolution 17, the Non Pre-emptive Amount (as defined in the Articles) shall be increased from GBP 2,278,140.10 to GBP ...(due to space limits, see proxy material for full proposal).

19.	That the Company be and is hereby generally and unconditionally authorized: (a) pursuant to Article 57 of the Companies (Jersey) Law 1991 to make market purchases of Ordinary Shares in the capital of the Company, provided that: (1) the maximum number of Ordinary Shares hereby authorized to be purchased is 91,125,605; (2) the minimum price, exclusive of any expenses, which may be paid for an Ordinary Share is five pence; (3) the maximum price, exclusive of any expenses, which may be paid ...(due to space limits, see proxy material for full proposal).	Management	For	For
20.	To approve that a general meeting of the Company, other than an annual general meeting, may be called on not less than 14 clear days' notice.	Management	For	For

## SPARK THERAPEUTICS, INC.

<b>Security</b>	84652J103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ONCE	<b>Meeting Date</b>	30-May-2018
<b>Record Date</b>	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Jeffrey D. Marrazzo		For	For
	2 Vincent J. Milano		For	For
	3 Elliott Sigal M.D. Ph.D		For	For
2.	To approve, on an advisory basis, the compensation paid to the Company's named executive officers.	Management	For	For
3.	To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

## SYNDAX PHARMACEUTICALS, INC

<b>Security</b>	87164F105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	SNDX	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	26-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Henry Chen	Management	For	For
1b.	Election of Director: Luke Evnin, Ph.D.	Management	For	For
2.	To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For

## TELIGENT, INC.

<b>Security</b>	87960W104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TLGT	<b>Meeting Date</b>	21-May-2018
<b>Record Date</b>	29-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Carole S. Ben-Maimon		For	For
	2 John Celentano		For	For
	3 Bhaskar Chaudhuri		For	For
	4 James C. Gale		For	For
	5 Jason Grenfell-Gardner		For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

	6	Steven Koehler		For	For
	7	Thomas J. Sabatino, Jr.		For	For
2.		Approve an amendment to the Teligent, Inc. 2016 Equity Incentive Plan to increase the number of shares of common stock reserved thereunder for issuance from 2,000,000 shares to a total of 4,000,000 shares.	Management	For	For
3.		To ratify the selection of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
4.		To approve by an advisory vote the compensation of the Company's named executive officers as disclosed in the proxy statement.	Management	For	For

---

## TESARO INC

<b>Security</b>	881569107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TSRO	<b>Meeting Date</b>	10-May-2018
<b>Record Date</b>	13-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Leon O. Moulder, Jr.		For	For
	2 Mary Lynne Hedley, Ph.D		For	For
	3 David M. Mott		For	For
	4 Lawrence M. Alleva		For	For
	5 James O. Armitage, M.D.		For	For
	6 Earl M. Collier, Jr.		For	For
	7 Garry A. Nicholson		For	For
	8 Kavita Patel, M.D.		For	For
	9 Beth Seidenberg, M.D.		For	For
	10 Pascale Witz		For	For
2.	To approve the Tesaro, Inc., Non-Employee Director Compensation Policy, including compensation amounts for 2018.	Management	For	For
3.	To approve, by non-binding vote, the Company's executive compensation.	Management	For	For
4.	To approve an amendment to the Tesaro, Inc., 2012 Employee Stock Purchase Plan to, among other things, increase the number of shares available for issuance thereunder by 275,000 shares.	Management	For	For
5.	To ratify the appointment of Ernst & Young, LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2018.	Management	For	For

## TETRAPHASE PHARMACEUTICALS, INC.

<b>Security</b>	88165N105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TTPH	<b>Meeting Date</b>	30-May-2018
<b>Record Date</b>	06-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Jeffrey Chodakewitz		For	For
	2 Gerri Henwood		For	For
	3 Guy Macdonald		For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of our named executive officers.	Management	For	For

## THE MEDICINES COMPANY

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	584688105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MDCO	<b>Meeting Date</b>	31-May-2018
<b>Record Date</b>	13-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1A.	Election of Director: Alexander J. Denner	Management	For	For
1B.	Election of Director: Fredric N. Eshelman	Management	For	For
1C.	Election of Director: Geno J. Germano	Management	For	For
1D.	Election of Director: John C. Kelly	Management	For	For
1E.	Election of Director: Clive A. Meanwell	Management	For	For
1F.	Election of Director: Paris Panayiotopoulos	Management	For	For
1G.	Election of Director: Sarah J. Schlesinger	Management	For	For
2.	Approve an amendment to our 2013 stock incentive plan in order to increase the number of shares of common stock authorized for issuance under the plan by 5,000,000 shares.	Management	For	For
3.	Approve, in an advisory vote, the compensation of our named executive officers as presented in the proxy statement.	Management	For	For
4.	Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

---

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**THERAPEUTICSMD, INC.**

<b>Security</b>	88338N107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TXMD	<b>Meeting Date</b>	25-Jun-2018
<b>Record Date</b>	26-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Tommy G. Thompson		For	For
	2 Robert G. Finizio		For	For
	3 John C.K. Milligan, IV		For	For
	4 Brian Bernick		For	For
	5 J. Martin Carroll		For	For
	6 Cooper C. Collins		For	For
	7 Robert V. LaPenta, Jr.		For	For
	8 Jules A. Musing		For	For
	9 Angus C. Russell		For	For
	10 Jane F. Barlow		For	For
	11 Nicholas Segal		For	For
2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2017 (say-on-pay).	Management	For	For
3.	To ratify the appointment of Grant Thornton LLP, an independent registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2018.	Management	For	For

**THERAVANCE BIOPHARMA, INC.**

<b>Security</b>	G8807B106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TBPH	<b>Meeting Date</b>	01-May-2018
<b>Record Date</b>	05-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Eran Broshty	Management	For	For
1.2	Election of Director: Laurie Smaldone Alsup	Management	For	For
1.3	Election of Director: Burton G. Malkiel	Management	For	For
2.	Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Adoption of the resolution approving a new shareholder rights plan and authorizing our board of directors to put the shareholder rights plan into effect in the future if and when the board of directors deems appropriate and in the best interests of the Company, which resolution is set forth as Annex A to the proxy statement.	Management	For	For

**THERMO FISHER SCIENTIFIC INC.**

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	883556102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TMO	<b>Meeting Date</b>	23-May-2018
<b>Record Date</b>	28-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1A.	Election of Director: Marc N. Casper	Management	For	For
1B.	Election of Director: Nelson J. Chai	Management	For	For
1C.	Election of Director: C. Martin Harris	Management	For	For
1D.	Election of Director: Tyler Jacks	Management	For	For
1E.	Election of Director: Judy C. Lewent	Management	For	For
1F.	Election of Director: Thomas J. Lynch	Management	For	For
1G.	Election of Director: Jim P. Manzi	Management	For	For
1H.	Election of Director: Lars R. Sorensen	Management	For	For
1I.	Election of Director: Scott M. Sperling	Management	For	For
1J.	Election of Director: Elaine S. Ullian	Management	For	For
1K.	Election of Director: Dion J. Weisler	Management	For	For
2.	An advisory vote to approve named executive officer compensation.	Management	For	For
3.	Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2018.	Management	For	For



**THEROX, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	24-Apr-2018
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	Approval of Second Certificate of Amendment to Eleventh Amended and Restated Certificate of Incorporation	Management	For	For
2.	Waiver of Participation Rights in Note Transaction	Management	For	For
3.	Approval of Amendment to Fourth Amended and Restated Investors Rights and Voting Agreement	Management	For	For
4.	Approval of Option Agreement with ZOLL	Management	For	For
5.	Approval of Agreement and Plan of Merger	Management	For	For
6.	Appointment of Shareholder Representative Services, LLC as Representative	Management	For	For
7.	Appointment of Representative Advisory Group Members	Shareholder	Against	For
8.	Ratification of Shadow Preferred Stock Issuance	Shareholder	Against	For
9.	General Authority	Shareholder	Against	For

**TRILLIUM THERAPEUTICS INC.**

<b>Security</b>	89620X506	<b>Meeting Type</b>	Annual and Special Meeting
<b>Ticker Symbol</b>	TRIL	<b>Meeting Date</b>	01-Jun-2018
<b>Record Date</b>	20-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1	<b>DIRECTOR</b>	Management		
	1 Mr. Luke Beshar		For	For
	2 Dr. Robert Kirkman		For	For
	3 Dr. Michael Moore		For	For
	4 Dr. Thomas Reynolds		For	For
	5 Dr. Niclas Stiernholm		For	For
	6 Dr. Calvin Stiller		For	For
	7 Dr. Helen Tayton-Martin		For	For
2	To reappoint Ernst & Young, LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Corporation for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors.	Management	For	For
3	Consider and, if deemed appropriate, approve the Corporation's amended and restated stock option plan, all as more particularly set out in the management information circular prepared by the Corporation in respect of the Meeting.	Management	Against	Against

**ULTRAGENYX PHARMACEUTICAL INC.**

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	90400D108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	RARE	<b>Meeting Date</b>	19-Jun-2018
<b>Record Date</b>	23-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1a.	Election of Director: Deborah Dunsire, M.D.	Management	For	For
1b.	Election of Director: Michael Narachi	Management	For	For
1c.	Election of Director: Clay B. Siegall, Ph.D.	Management	For	For
2.	Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Advisory (non-binding) vote to approve the compensation of our named executive officers.	Management	For	For

## UNIQUE N.V.

<b>Security</b>	N90064101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	QURE	<b>Meeting Date</b>	13-Jun-2018
<b>Record Date</b>	16-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Resolution to adopt the 2017 annual accounts and treatment of the results.	Management	For	For
2.	Resolution to discharge liability of the members of the Board for their management.	Management	For	For
3a.	Appointment of Philip Astley-Sparke as non-executive director.	Management	For	For
3b.	Appointment of Robert Gut as non-executive director.	Management	For	For
3c.	Appointment of David Meek as non-executive director.	Management	For	For
4.	Amendment to the 2014 Restated Plan.	Management	For	For
5.	Resolution to designate the Board as the competent body to issue ordinary shares and options and to exclude preemptive rights under the 2014 Restated Plan.	Management	For	For
6.	Approval of the employee share purchase plan.	Management	For	For
7.	Resolution to redesignate the Board as the competent body to issue ordinary shares and options and to limit or exclude pre-emptive rights.	Management	For	For
8.	Authorization of the Board to repurchase ordinary shares.	Management	For	For
9.	Resolution to reappoint PricewaterhouseCoopers Accountants N.V. as auditor of the Company for the 2018 financial year ending at the close of the Annual General Meeting.	Management	For	For

## UNITED THERAPEUTICS CORPORATION

<b>Security</b>	91307C102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	UTHR	<b>Meeting Date</b>	26-Jun-2018
<b>Record Date</b>	30-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Katherine Klein	Management	For	For
1b.	Election of Director: Ray Kurzweil	Management	For	For
1c.	Election of Director: Martine Rothblatt	Management	For	For
1d.	Election of Director: Louis Sullivan	Management	For	For
2.	Advisory resolution to approve executive compensation.	Management	For	For
3.	Approval of the amendment and restatement of the United Therapeutics Corporation 2015 Stock Incentive Plan.	Management	For	For
4.	Ratification of the appointment of Ernst & Young LLP as United Therapeutics Corporation's independent registered public accounting firm for 2018.	Management	For	For

## VERONA PHARMA PLC

<b>Security Ticker Symbol Record Date</b>	GB00BYW2KH80 VRP N/A	<b>Meeting Type Meeting Date</b>	Annual General Meeting 02-May-2018
---	----------------------------	----------------------------------	---------------------------------------

Item	Proposal	Proposed by	Vote	For/Against Management
1	TO RECEIVE AND ADOPT THE REPORT OF THE DIRECTORS AND THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017	Management	For	For
2	TO APPROVE THE DIRECTORS REMUNERATION POLICY	Management	For	For
3	TO APPROVE THE DIRECTORS REMUNERATION REPORT	Management	For	For
4	TO RE-ELECT DAVID RAYMOND EBSWORTH AS A DIRECTOR OF THE COMPANY	Management	For	For
5	TO RE-ELECT SVEN ANDERS ULLMAN AS A DIRECTOR OF THE COMPANY	Management	For	For
6	TO APPOINT PRICEWATERHOUSECOOPERS LLP AS AUDITORS	Management	For	For
7	TO AUTHORISE THE DIRECTORS TO DETERMINE THE AUDITORS REMUNERATION	Management	For	For
8	TO AUTHORISE THE DIRECTORS TO ALLOT RELEVANT SECURITIES PURSUANT TO SECTION 551 OF THE COMPANIES ACT 2006	Management	For	For
9	TO AUTHORISE THE DIRECTORS TO ALLOT EQUITY SECURITIES PURSUANT TO SECTION 570 OF THE COMPANIES ACT 2006	Management	For	For

## VERONA PHARMA PLC

<b>Security Ticker Symbol Record Date</b>	925050106 VRNA 06-Mar-2018	<b>Meeting Type Meeting Date</b>	Annual 02-May-2018
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
O1	To receive and adopt the report of the directors and the financial statements for the year ended 31 December 2017.	Management	For	For
O2	To approve the Directors Remuneration Policy.	Management	For	For
O3	To approve the Directors Remuneration Report.	Management	For	For
O4	To re-elect David Raymond Ebsworth as a director of the Company.	Management	For	For
O5	To re-elect Sven Anders Ullman as a director of the Company.	Management	For	For
O6	To appoint PricewaterhouseCoopers LLP as auditors.	Management	For	For
O7	To authorise the directors to determine the auditors remuneration.	Management	For	For
O8		Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

To authorise the directors to allot relevant securities pursuant to Section 551 of the Companies Act 2006.

S9	To authorise the directors to allot equity securities pursuant to Section 570 of the Companies Act 2006.	Management	For	For
----	--	------------	-----	-----

VERONA PHARMA PLC

<b>Security</b>	GB00BYW2KH80	<b>Meeting Type</b>	Ordinary General Meeting
<b>Ticker Symbol</b>	VRP	<b>Meeting Date</b>	26-Jun-2018
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	TO AUTHORISE THE DIRECTORS TO ALLOT RELEVANT SECURITIES PURSUANT TO SECTION 551 OF THE COMPANIES ACT 2006	Management	For	For
2	TO AUTHORISE THE DIRECTORS TO ALLOT EQUITY SECURITIES AND/OR SELL TREASURY SECURITIES FOR CASH PURSUANT TO SECTION 570 AND 573 OF THE COMPANIES ACT 2006	Management	For	For

## VERONA PHARMA PLC

<b>Security</b>	925050106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	VRNA	<b>Meeting Date</b>	26-Jun-2018
<b>Record Date</b>	24-May-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
O1.	To authorise the directors to allot relevant securities pursuant to Section 551 of the Companies Act 2006.	Management	For	For
S2.	To authorise the directors to allot equity securities and/or sell treasury securities for cash pursuant to Section 570 and 573 of the Companies Act 2006.	Management	For	For

## VERTEX PHARMACEUTICALS INCORPORATED

<b>Security</b>	92532F100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	VRTX	<b>Meeting Date</b>	17-May-2018
<b>Record Date</b>	29-Mar-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.1	Election of Class I Director: Sangeeta N. Bhatia	Management	For	For
1.2	Election of Class I Director: Jeffrey M. Leiden	Management	For	For
1.3	Election of Class I Director: Bruce I. Sachs	Management	For	For
2.	Amendments to our charter and by-laws to eliminate supermajority provisions.	Management	For	For
3.	Amendment and restatement of our 2013 Stock and Option Plan, to among other things, increase the number of shares available under the plan by 8.0 million shares.	Management	For	For
4.	Ratification of Ernst & Young LLP as our Independent Registered Public Accounting firm for the year ending December 31, 2018.	Management	For	For
5.	Advisory vote on named executive officer compensation.	Management	For	For
6.	Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on the risks to us of rising drug prices.	Shareholder	Against	For
7.	Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on our policies and activities with respect to lobbying.	Shareholder	Against	For

## XENCOR INC

<b>Security</b>	98401F105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	XNCR	<b>Meeting Date</b>	26-Jun-2018
<b>Record Date</b>	27-Apr-2018		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR			
	1	Dr. Kevin C. Gorman	For	For
	2	Dr. A. Bruce Montgomery	For	For
	3	Dr. Bassil I. Dahiyat	For	For
	4	Mr. Kurt Gustafson	For	For
	5	Mr. Yujiro S. Hata	For	For
	6	Mr. Richard Ranieri	For	For
2.	Proposal to ratify RSM US LLP as the independent public accounting firm for 2018.	Management	For	For
3.	Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy materials.	Management	For	For

## XENON PHARMACEUTICALS INC

<b>Security</b>	98420N105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	XENE	<b>Meeting Date</b>	04-Jun-2018
<b>Record Date</b>	09-Apr-2018		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1	Michael Tarnow	For	For
	2	Mohammad Azab	For	For
	3	Steven Gannon	For	For
	4	Michael Hayden	For	For
	5	Frank Holler	For	For
	6	Gary Patou	For	For
	7	Simon Pimstone	For	For
	8	Richard Scheller	For	For
	9	Dawn Svoronos	For	For
2.	Appointment of KPMG LLP as Auditor	Management	For	For
3.	Authorizing the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the Auditor	Management	For	For

---



**SIGNATURES**

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant)                      Tekla Life Sciences Investors

By (Signature and Title)\*

/s/ Daniel R. Omstead  
(Daniel R. Omstead, President)

Date                                      8/20/18

---

\*Print the name and title of each signing officer under his or her signature.